C07J 41/0016
Oximes
Official title: {Oximes}
C07J41/0016 (Oximes) appears on 153 US grants and 102 published applications in this corpus.
Search patents in C07J- Granted patents
- 153
- Published applications
- 102
- Assignees
- 89
- Inventors
- 336
- Latest grant
- 2 Dec 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 4 | 0 |
| 1977 | 4 | 0 |
| 1978 | 3 | 0 |
| 1979 | 1 | 0 |
| 1980 | 12 | 0 |
| 1981 | 3 | 0 |
| 1982 | 3 | 0 |
| 1983 | 4 | 0 |
| 1984 | 4 | 0 |
| 1985 | 4 | 0 |
| 1986 | 5 | 0 |
| 1987 | 3 | 0 |
| 1988 | 2 | 0 |
| 1989 | 2 | 0 |
| 1990 | 1 | 0 |
| 1991 | 6 | 0 |
| 1992 | 1 | 0 |
| 1993 | 3 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 2 | 0 |
| 1997 | 7 | 0 |
| 1998 | 6 | 0 |
| 1999 | 4 | 0 |
| 2000 | 4 | 0 |
| 2001 | 4 | 1 |
| 2002 | 1 | 3 |
| 2003 | 2 | 0 |
| 2004 | 1 | 3 |
| 2005 | 4 | 6 |
| 2006 | 2 | 3 |
| 2007 | 1 | 1 |
| 2008 | 1 | 2 |
| 2009 | 1 | 2 |
| 2010 | 2 | 6 |
| 2011 | 1 | 4 |
| 2012 | 0 | 4 |
| 2013 | 6 | 6 |
| 2014 | 3 | 6 |
| 2015 | 2 | 6 |
| 2016 | 3 | 5 |
| 2017 | 6 | 5 |
| 2018 | 2 | 5 |
| 2019 | 5 | 1 |
| 2020 | 2 | 5 |
| 2021 | 2 | 6 |
| 2022 | 3 | 4 |
| 2023 | 3 | 5 |
| 2024 | 2 | 4 |
| 2025 | 4 | 4 |
| 2026 | 0 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- GPX4 inhibitors and senolytic compounds and uses thereof2 Dec 2025US 12,485,132 B2Rubedo Life Sciences, Inc.
- Progesterone analogs and uses related thereto4 Nov 2025US 12,459,970 B2Emory University
- Progesterone phosphate analogs and uses related thereto16 Sep 2025US 12,415,829 B2Emory University
- Coumarin-modified androgens for the treatment of prostate cancer24 Jun 2025US 12,337,004 B2Health Research, Inc.
- Polyethylene glycol-conjugated glucocorticoid prodrugs and compositions and methods thereof18 Jun 2024US 12,011,450 B2Board of Regents of the University of Nebraska
- 3-alpha substituted 3-beta-hydroxy-17-oximated androstane compound for modulation of the alpha-3 subtype of the gabaa receptor10 Sep 2026US 2026/0265290 A1Umecrine Cognition AB
- Coumarin-modified androgens for the treatment of prostate cancer30 Apr 2026US 2026/0115207 A1Health Research, Inc.
- Compositions and methods for treating cns disorders9 Apr 2026US 2026/0098053 A1Sage Therapeutics, Inc.
- Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same5 Feb 2026US 2026/0034146 A1Sage Therapeutics, Inc.
- GPX4 Inhibitors and Senolytic Compounds and Uses Thereof8 Jan 2026US 2026/0007689 A1Rubedo Life Sciences, Inc.
Most cited
By later US patents
- Oligonucleotide having enhanced binding affinity276US 5,486,603 AGilead Sciences, Inc. · 1996
- Label modified immunoassays229US 4,208,479 ASyva Company · 1980
- 4-Aza-17.beta.-substituted-5.alpha.-androstan-3-one-reductase inhibitors159US 4,377,584 AMerck & Co., Inc. · 1983
- Nucleophilic polysubstituted aryl acridinium esters and uses thereof85US 5,241,070 ACiba Corning Diagnostics Corp. · 1993
- Fluorescent polarization assay for ligands using aminomethylfluorescein derivatives as tracers75US 4,510,251 AAbbott Laboratories · 1985